tradingkey.logo

Airnexis Therapeutics Raises $200 Million Series A

ReutersJan 9, 2026 1:48 PM

-

  • AIRNEXIS THERAPEUTICS LAUNCHES WITH $200M SERIES A TO ADVANCE PHASE 2 DUAL PDE3/4 INHIBITOR AN01 FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

  • AIRNEXIS THERAPEUTICS: OVER-SUBSCRIBED SERIES A WAS LED BY FRAZIER LIFE SCIENCES

Further company coverage: [ ]

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI